Friday, February 8, 2013

• ShinesRooms Research on Gilead and Hemispherx: Biotech Companies Seek New PasturesAccesswire (Fri, Feb 8)

Wednesday, February 6, 2013

• Levi & Korsinsky Notifies Investors With Losses on Their Investment in Hemispherx Biopharma, Inc. of Class Action Lawsuit and the Deadline of March 5, 2013 to Seek a Lead Plaintiff PositionMarketwired (Wed, Feb 6)

Tuesday, February 5, 2013

• Cohen Milstein Sellers & Toll PLLC Continues to Investigate Hemispherx Biopharma, Inc. Following the FDA’s Rejection of the Ampligen New Drug ApplicationBusiness Wire (Tue, Feb 5)
• HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other EventsEDGAR Online (Tue, Feb 5)
• Hunger striker continues after FDA rejects Hemispherx drug: Interviewat bizjournals.com (Tue, Feb 5)
• Hemispherx chronic fatigue drug Ampligen rejected by FDAat bizjournals.com (Tue, Feb 5)
• Hemispherx's Chronic Fatigue Drug Rejected by FDAat Minyanville (Tue, Feb 5)

Friday, February 1, 2013

• Biotech Companies Attractive Targets for Pharma Companies Looking to Replace Lost RevenuesMarketwired (Fri, Feb 1)

Thursday, January 31, 2013

• 5 High-Profile Drugs Expect FDA Decisions in Februaryat Minyanville (Thu, Jan 31)

Wednesday, January 16, 2013

• Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Hemispherx Biopharma, Inc.Business Wire (Wed, Jan 16)

Friday, January 11, 2013

• HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online (Fri, Jan 11)

Friday, December 21, 2012

• HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other EventsEDGAR Online (Fri, Dec 21)
• 2 Biotech Stocks That Could Be Prime Candidates For The Short Sellerat Seeking Alpha (Fri, Dec 21)
• FDA panel nixes Hemispherx’s Ampligen drugat bizjournals.com (Fri, Dec 21)

Wednesday, December 19, 2012

• Amgen Licenses ImmunoGen Tech, Hemispherx Drug Questioned by FDA: Healthcare Business Recapat Wall St. Cheat Sheet (Wed, Dec 19)
• Stock Watch Wednesday, 19 Decemberat Seeking Alpha (Wed, Dec 19)
• Hemispherx Faces FDA Dayat Seeking Alpha (Wed, Dec 19)

Tuesday, December 18, 2012

• Hemispherx's Unsurprising 45% Plungeat Motley Fool (Tue, Dec 18)
• Hemispherx Chronic Fatigue Drug Scrutinized Ahead of Panel Reviewat Minyanville (Tue, Dec 18)
• Hemispherx Lied To Investors And SEC About Ampligenat TheStreet (Tue, Dec 18)
• FDA staff identified 'multiple concerns' with efficacy analyses for Ampligenat theflyonthewall.com (Tue, Dec 18)
• Strong Small Cap Biopharma Catalyst Trades And Investments For Considerationat Seeking Alpha (Tue, Dec 18)
• Hemispherx's Ampligen Is Unlikely To Receive FDA Approvalat Seeking Alpha (Tue, Dec 18)

Monday, December 17, 2012

• Hemispherx's fatigue drug to be reviewed again by FDA, WSJ reportstheflyonthewall.com (Mon, Dec 17)

Sunday, December 16, 2012

• 4 Stories to Watch This Week in the Health-Care Sectorat Motley Fool (Sun, Dec 16)

Add HEB News to My Yahoo!